Vmbook Online ordering

Icons

ICON plc, trading under the ticker symbol “ICLR” on the NASDAQ stock exchange, is a global provider of clinical research services and technology solutions to pharmaceutical, biotechnology, and medical device industries. The company was founded in 1990 and is headquartered in Dublin, Ireland.

ICLR has a market capitalization of approximately $6.4 billion as of February 2023, making it a mid-size company in terms of market value. The stock has experienced significant growth in recent years, with its share price increasing by over 150% in the past 5 years. This growth has been driven by the company's strong financial performance and expanding presence in the clinical research services market.

ICLR's revenue for the most recent fiscal year was $2.6 billion, representing a 12% increase from the previous year. The company's net income for the same period was $167.6 million, a 14% increase from the previous year. These strong financial results have been driven by the company's ability to secure new contracts and expand its services to existing clients.

ICLR has consistently reported positive earnings and revenue growth, making it an attractive investment for many investors. The company's earnings per share (EPS) for the most recent fiscal year was $4.11, a 17% increase from the previous year. This growth in EPS has been driven by the company's ability to generate strong revenue growth while maintaining tight control over its operating expenses.

ICLR has also demonstrated a strong track record of returning value to shareholders. The company has paid a dividend consistently for several years, with a current yield of 0.6%. The company has also repurchased shares in the open market, demonstrating its confidence in the long-term prospects of the business.

Overall, ICLR is a publicly traded company with a strong financial performance, consistent growth, and a focus on delivering value to shareholders. Its position as a leading provider of clinical research services and technology solutions to the pharmaceutical, biotechnology, and medical device industries has helped it to achieve significant success in the stock market.